Has a very strong reactive immune system; Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm; Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm; Had headache that was pretty bad; Her arm was painful and itchy/left arm was painful; Her arm was painful and itchy; Redness and pain from injection site half way down the arm; Covid arm, have that redness and pain from injection site half way down the arm was reported as worsened; Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm; rash was hot to touch and itched; rash was hot to touch and itched; a red rash extended from injection site half way down arm to elbow; Arm was swollen; She had a fever of 101.9F/ fever 27Sep 100.5 and 28Sep 100.9 orally/Mild fever; skin reaction for 4 days- mild; Sinus pressure; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 75 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 27Sep2021 09:00 (Lot number: 303308a, Expiration Date: Oct2022) at the age of 75 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: FLUAD QUAD taken for immunisation, administration date 07Sep2021. Vaccination history included: Bnt162b2 (First dose), administration date: 01Jan2021, when the patient was 74 years old, for COVID-19 immunization; Bnt162b2 (Second dose), administration date: 28Jan2021, when the patient was 74 years old, for COVID-19 immunization, reaction(s): "fever", "redness", "pain in arm", "swollen glands under the arms", "Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm", "Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm", "Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm", "Redness and pain from injection site half way down the arm". The following information was reported: PYREXIA (non-serious) with onset 27Sep2021, outcome "recovered" (29Sep2021), described as "She had a fever of 101.9F/ fever 27Sep 100.5 and 28Sep 100.9 orally/Mild fever"; VACCINATION SITE PAIN (non-serious), VACCINATION SITE SWELLING (non-serious) all with onset 28Sep2021 09:00, outcome "recovered" and all described as "Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm"; LIMB DISCOMFORT (non-serious) with onset 28Sep2021, outcome "recovered", described as "Had the COVID arm which is characterized by pain and swelling at the injection site that spread down her arm"; HEADACHE (non-serious) with onset 28Sep2021 09:00, outcome "recovered" (29Sep2021), described as "Had headache that was pretty bad"; PARANASAL SINUS DISCOMFORT (non-serious) with onset 27Sep2021, outcome "recovered" (30Sep2021), described as "Sinus pressure"; PAIN IN EXTREMITY (non-serious) with onset 28Sep2021 09:00, outcome "not recovered", described as "Her arm was painful and itchy/left arm was painful"; PRURITUS (non-serious) with onset 28Sep2021 09:00, outcome "not recovered", described as "Her arm was painful and itchy"; VACCINATION SITE ERYTHEMA (non-serious) with onset 28Sep2021 09:00, outcome "not recovered", described as "Redness and pain from injection site half way down the arm"; CONDITION AGGRAVATED (non-serious) with onset 28Sep2021, outcome "not recovered", described as "Covid arm, have that redness and pain from injection site half way down the arm was reported as worsened"; IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "Has a very strong reactive immune system"; FEELING HOT (non-serious), RASH PRURITIC (non-serious) all with onset 28Sep2021, outcome "recovered" (06Oct2021) and all described as "rash was hot to touch and itched"; RASH ERYTHEMATOUS (non-serious) with onset 28Sep2021, outcome "recovered" (06Oct2021), described as "a red rash extended from injection site half way down arm to elbow"; SKIN REACTION (non-serious) with onset 27Sep2021, outcome "recovered" (01Oct2021), described as "skin reaction for 4 days- mild"; PERIPHERAL SWELLING (non-serious) with onset 28Sep2021, outcome "unknown", described as "Arm was swollen". The patient underwent the following laboratory tests and procedures: body temperature: (28Sep2021) 101.9 Fahrenheit; (27Sep2021) 100.5 Fahrenheit; (28Sep2021) 100.9 Fahrenheit, notes: orally; (29Sep2021) normal. Therapeutic measures were taken as a result of pyrexia, vaccination site pain, vaccination site swelling, limb discomfort, headache, pain in extremity.   Additional information: The reporter is a consumer reporting, she received the first two doses of Pfizer Covid 19 Vaccine back in Jan2021 and received the booster dose Pfizer Covid 19 Vaccine on Monday, 27Sep2021. She had a fever of 101.9F. Fever began on 28Sep2021, the second day after receiving booster dose Pfizer Covid 19 Vaccine and went back to normal yesterday, 29Sep2021. The caller stated she recovered completely. The patient temperature was normal now. The patient received 3 days Tylenol and Benadryl treatment for the events. On second day, 28Sep2021 left arm was painful and a red rash extended from injection site half way down arm to elbow; the rash was hot to touch and itched, Arm was swollen; rash lasted 8 days after 28Sep2021. When rash subsided completely; fever 27Sep 100.5 and 28Sep 100.9 orally; headache accompanied skin reaction for 4 days- mild. Reaction identical to what occurred on 2nd vaccination on 28Jan2021. She also had headache and sinus pressure. With her past experience with the Pfizer COVID-19 vaccine, she said that her arm was painful and itchy. It happened again this time. It was the 4th day since she had the booster shot and she said that it was getting worse. Covid arm, have that redness and pain from injection site half way down the arm was reported as worsened.    No follow-up attempts are possible. No further information is expected.